Champions Oncology, Inc. (CSBR)
Chart Events
Performance Outlook
| Previous Close | 7.30 |
| Open | 7.26 |
| Bid | 2.86 x 900 |
| Ask | 7.18 x 2200 |
| Day's Range | 6.81 - 7.38 |
| 52 Week Range | 6.81 - 11.25 |
| Volume | |
| Avg. Volume | 6,113 |
| Market Cap | 92.036M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | 340.50 |
| EPS (TTM) | 0.02 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.67 |
- ACCESSWIRE
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo
HACKENSACK, NJ / ACCESSWIRE / May 3, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today that its Lumin Bioinformatics Platform has been selected as a finalist for the ‘Best in Show' Competition at the upcoming Bio-IT World Conference & Expo.
- Simply Wall St.
Champions Oncology, Inc.'s (NASDAQ:CSBR) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Champions Oncology (NASDAQ:CSBR) has had a rough month with its share price down 7.0%. However, stock prices are...
- ACCESSWIRE
Champions Oncology Reports Record Quarterly Revenue of $13.2 Million Reported Adjusted EBITDA of $1.5 million
HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2022, ended January 31, 2022.
